Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

EndoCells

EndoCells
2004 FOUNDED
OOB STATUS
1-10 EMPLOYEES
Out of Business LATEST DEAL TYPE
Description

Developer of a novel proprietary pancreatic beta islet cell immortalization technology intended to focus on generation and development of human endocrine cell lines. The company's novel proprietary pancreatic beta islet cell immortalization technology provides a sustainable source of cells for drug screening and cell transplantation therapy of Type 1 diabetes, enabling patients to get faster recovery from diabetes.

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Drug Discovery
Primary Office
  • 216 Boulevard Saint Germain
  • 75007 Paris
  • France
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore EndoCells’s full profile, request a free trial.

EndoCells Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Oct-2017 Completed Out of Business
1. Early Stage VC Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

EndoCells Executive Team (5)

Name Title Board
Seat
Contact
Info
Anne-Fabienne Weitsch Ph.D Chief Executive Officer
Paul Czernichow MD President
Philippe Ravassard Ph.D Co-Founder
Raphael Scharfmann Ph.D Co-Founder

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »